drugset / Trial / NCT00607451
Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetic and pharmacodynamic effects of single doses of Neu-120 in Parkinson's disease patients with levodopa-induced dyskinesia.
Timeline
- Start
- 2008-03
- Primary completion
- 2016-08-27
- Completion
- 2016-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neu-120 | Unknown | 300 mg | Oral |
| Subject | Neu-120 | Unknown | 900 mg | Oral |
| Subject | Neu-120 | Unknown | 2700 mg | Oral |